Botulinum toxin E - Bonti

Drug Profile

Botulinum toxin E - Bonti

Alternative Names: BoNT/E; EB-001

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bonti
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants; Recombinant proteins
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glabellar lines; Musculoskeletal pain

Most Recent Events

  • 24 Nov 2017 Bonti plans a phase II trial for Scars in January 2018 (NCT03346902)
  • 23 Aug 2017 Phase-II clinical trials in Musculoskeletal pain in USA (IM) (NCT03193593)
  • 23 Aug 2017 Bonti plans the phase II LANTERN-2 trial for Musculoskeletal pain in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top